Drug intelligence / Profile preview

cyclophosphamide + methylprednisolone + prednisone

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous, Oral
01

Overview

This is a combination regimen of three drugs—cyclophosphamide, methylprednisolone, and prednisone—used primarily as an immunosuppressive and anti-inflammatory therapy in severe autoimmune diseases such as lupus nephritis and systemic vasculitis. Cyclophosphamide is an alkylating agent that suppresses the immune system by cross-linking DNA, leading to cell death in rapidly dividing cells including lymphocytes. Methylprednisolone and prednisone are synthetic glucocorticoid corticosteroids that reduce inflammation by inhibiting leukocyte migration and suppressing immune responses. This combination aims to maximize immunosuppression for disease control while balancing toxicity risks[1][4][5].

Other names
cyclophosphamide and steroidscyclophosphamide + steroids
02

Targets

DNAGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on cyclophosphamide + methylprednisolone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + methylprednisolone + prednisone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call